相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial
Moeko Noguchi-Shinohara et al.
JOURNAL OF ALZHEIMERS DISEASE (2023)
The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease
Senthilkumar S. Karuppagounder et al.
SCIENCE TRANSLATIONAL MEDICINE (2023)
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Andrew Siderowf et al.
LANCET NEUROLOGY (2023)
Structural Dynamics of Amyloid-β Protofibrils and Actions of Anti- Amyloid-β Antibodies as Observed by High-Speed Atomic Force Microscopy
Takahiro Watanabe-Nakayama et al.
NANO LETTERS (2023)
Plasma amyloid-β biomarkers are associated with Alzheimer′s disease comorbidity in Lewy body disease
Moeko Noguchi-Shinohara et al.
PARKINSONISM & RELATED DISORDERS (2023)
Chalcone Analogue as New Candidate for Selective Detection of α-Synuclein Pathology
Sho Kaide et al.
ACS CHEMICAL NEUROSCIENCE (2022)
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy
Leonidas Chouliaras et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)
APOE4 exacerbates α-synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology
Yunjung Jin et al.
ACTA NEUROPATHOLOGICA (2022)
Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond
Chenghuan Song et al.
TRANSLATIONAL NEURODEGENERATION (2022)
Interactions of amyloid coaggregates with biomolecules and its relevance to neurodegeneration
Kazuma Murakami et al.
FASEB JOURNAL (2022)
Monoclonal Antibody Therapy in Parkinson's Disease - The End?
Alan Whone
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Trial of Prasinezumab in Early-Stage Parkinson's Disease
G. Pagano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Trial of Cinpanemab in Early Parkinson's Disease
A. E. Lang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis
Maider Zubelzu et al.
PARKINSONISM & RELATED DISORDERS (2022)
Evaluation of the ?-synuclein PET radiotracer (d3)-[11C]MODAG-001 in pigs
Nakul Ravi Raval et al.
NUCLEAR MEDICINE AND BIOLOGY (2022)
Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease
Hiroaki Sekiya et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2022)
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
Zerui Wang et al.
JAMA NEUROLOGY (2021)
[11C]MODAG-001-towards a PET tracer targeting α-synuclein aggregates
Laura Kuebler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease
Sara Hall et al.
MOVEMENT DISORDERS (2021)
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study
Alex Iranzo et al.
LANCET NEUROLOGY (2021)
In vitro comparison of major memory-support dietary supplements for their effectiveness in reduction/inhibition of beta-amyloid protein fibrils and tau protein tangles: key primary targets for memory loss
Alan D. Snow et al.
SCIENTIFIC REPORTS (2021)
Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies
Connor Bargar et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2021)
Alpha-Synuclein PET Tracer Development-An Overview about Current Efforts
Spela Korat et al.
PHARMACEUTICALS (2021)
Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology
Fares Bassil et al.
NEURON (2020)
Dopaminergic Depletion, β-Amyloid Burden, and Cognition in Lewy Body Disease
Han Soo Yoo et al.
ANNALS OF NEUROLOGY (2020)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
Thomas K. Karikari et al.
LANCET NEUROLOGY (2020)
Self- and Cross-Seeding on α-Synuclein Fibril Growth Kinetics and Structure Observed by High-Speed Atomic Force Microscopy
Takahiro Watanabe-Nakayama et al.
ACS NANO (2020)
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
Lana M. Chahine et al.
NEUROLOGY (2020)
Blinded RT-QuIC Analysis of α-Synuclein Biomarker in Skin Tissue from Parkinson's Disease Patients
Sireesha Manne et al.
MOVEMENT DISORDERS (2020)
Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression
Moeko Noguchi-Shinohara et al.
SCIENTIFIC REPORTS (2020)
α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis
Surabhi Mehra et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2019)
Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naive Parkinson's disease
Hidetomo Murakami et al.
BMC NEUROLOGY (2019)
Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease
Takuya Uehara et al.
SCIENTIFIC REPORTS (2019)
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
Inger van Steenoven et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease
Chin-Hsien Lin et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Inflammasome and α-synuclein in Parkinson's disease: A cross-sectional study
Koustav Chatterjee et al.
JOURNAL OF NEUROIMMUNOLOGY (2019)
Distinct Patterns of Amyloid-Dependent Tau Accumulation in Lewy Body Diseases
Seung Ha Lee et al.
MOVEMENT DISORDERS (2018)
Cerebrospinal Fluid, Plasma, and Saliva in the BioFIND Study: Relationships Among Biomarkers and Parkinson's Disease Features
Jennifer G. Goldman et al.
MOVEMENT DISORDERS (2018)
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders
David J. Irwin et al.
NEUROLOGY (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
The Parkinson Pandemic-A Call to Action
E. Ray Dorsey et al.
JAMA NEUROLOGY (2018)
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease
Diana L. Price et al.
SCIENTIFIC REPORTS (2018)
Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies
A. W. Lemstra et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk et al.
MOVEMENT DISORDERS (2017)
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
David Irwin et al.
LANCET NEUROLOGY (2017)
The Oligomer Hypothesis in α-Synucleinopathy
Kenjiro Ono
NEUROCHEMICAL RESEARCH (2017)
Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium
Ian G. McKeith et al.
NEUROLOGY (2017)
Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder
Elena Antelmi et al.
NEUROLOGY (2017)
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia
Davide Chiasserini et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Interactions of pathological proteins in neurodegenerative diseases
Tara L. Spires-Jones et al.
ACTA NEUROPATHOLOGICA (2017)
Dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson's disease
A. Emelyanov et al.
DATA IN BRIEF (2017)
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease
Mark Terrelonge et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2016)
Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort
Inger Van Steenoven et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
The Genetic Basis of Cognitive impairment and Dementia in Parkinson's Disease
Lucy M. Collins et al.
FRONTIERS IN PSYCHIATRY (2016)
Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson's disease patients
Wenyan Kang et al.
SCIENTIFIC REPORTS (2016)
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
Jens Wagner et al.
ACTA NEUROPATHOLOGICA (2015)
Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain
Rosalind F. Roberts et al.
BRAIN (2015)
Impaired planning in Parkinson's disease is reflected by reduced brain activation and connectivity
James P. Trujillo et al.
HUMAN BRAIN MAPPING (2015)
Phenolic compounds prevent the oligomerization of -synuclein and reduce synaptic toxicity
Ryoichi Takahashi et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Pharmacokinetics, Safety and Tolerability of Melissa officinalisExtract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial
Moeko Noguchi-Shinohara et al.
PLOS ONE (2015)
The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios
Heike J. Wobst et al.
FEBS LETTERS (2015)
Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease
Yaroslau Compta et al.
JOURNAL OF NEUROLOGY (2015)
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
Johannes Levin et al.
ACTA NEUROPATHOLOGICA (2014)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
Lucilla Parnetti et al.
MOVEMENT DISORDERS (2014)
Submandibular gland needle biopsy for the diagnosis of Parkinson disease
Charles H. Adler et al.
NEUROLOGY (2014)
Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease
Marwan S. M. Al-Nimer et al.
NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES (2014)
Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons
Jing L. Guo et al.
CELL (2013)
Confluence of α-Synuclein, Tau, and β-Amyloid Pathologies in Dementia With Lewy Bodies
Marti Colom-Cadena et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study
Alex Iranzo et al.
LANCET NEUROLOGY (2013)
Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent
Devika P. Bagchi et al.
PLOS ONE (2013)
A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease
Penelope G. Foulds et al.
SCIENTIFIC REPORTS (2013)
Correlation between motor and cognitive functions in the progressive course of Parkinson's disease
Hidetomo Murakami et al.
NEUROLOGY AND CLINICAL NEUROSCIENCE (2013)
Phenolic Compounds Prevent Amyloid β-Protein Oligomerization and Synaptic Dysfunction by Site-specific Binding
Kenjiro Ono et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Cross-seeding effects of amyloid β-protein and α-synuclein
Kenjiro Ono et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Multimodality imaging characteristics of dementia with Lewy bodies
Kejal Kantarci et al.
NEUROBIOLOGY OF AGING (2012)
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
N. S. M. Schoonenboom et al.
NEUROLOGY (2012)
Phosphorylated α-Synuclein in Parkinson's Disease
Yu Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
Min Shi et al.
ANNALS OF NEUROLOGY (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study (vol 10, pg 230, 2011)
B. Mollenhauer et al.
LANCET NEUROLOGY (2011)
Cerebrospinal Fluid Tau/α-Synuclein Ratio in Parkinson's Disease and Degenerative Dementias
Lucilla Parnetti et al.
MOVEMENT DISORDERS (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer et al.
LANCET NEUROLOGY (2011)
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda et al.
NEUROLOGY (2010)
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
A. Siderowf et al.
NEUROLOGY (2010)
Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models
Damla Pinar Karpinar et al.
EMBO JOURNAL (2009)
In vitro characterisation of BF227 binding to α-synuclein/Lewy bodies
Michelle T. Fodero-Tavoletti et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Structural insights on physiological functions and pathological effects of α-synuclein
Marco Bisaglia et al.
FASEB JOURNAL (2009)
The Priamo Study: A Multicenter Assessment of Nonmotor Symptoms and Their Impact on Quality of Life in Parkinson's Disease
Paolo Barone et al.
MOVEMENT DISORDERS (2009)
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
P. Edison et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Mariese A. Hely et al.
MOVEMENT DISORDERS (2008)
Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
Igor F. Tsigelny et al.
PLOS ONE (2008)
Different species of α-synuclein oligomers induce calcium influx and seeding
Karin M. Danzer et al.
JOURNAL OF NEUROSCIENCE (2007)
Interaction between Aβ peptide and α synuclein:: Molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease
Pravat K. Mandal et al.
NEUROCHEMICAL RESEARCH (2006)
Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro
K Ono et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease
Omar M. A. El-Agnaf et al.
FASEB JOURNAL (2006)
Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium
IG McKeith et al.
NEUROLOGY (2005)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro
K Ono et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2004)
Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42
A Maddalena et al.
ARCHIVES OF NEUROLOGY (2003)
Initiation and synergistic fibrillization of tau and alpha-synuclein
BI Giasson et al.
SCIENCE (2003)
β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
E Masliah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
